Роль простагландина Е2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом

Цель. Изучить роль простагландина Е2 (ПГЕ2) в ингибировании расщепления коллагена 2 типа эксплантатами суставного хряща больных остеоартрозом (ОА). Материал и методы. Эксплантаты хрящей больных ОА культивировали в присутствии ПГЕ2 в концентрации от 1пг до 10нг/мл. Расщепление коллагена 2 типа оценивали, используя иммуноферментный анализ. Экспрессию генов определяли посредством ПЦР в реальном времени. Результаты. В эксплантатах хрящей больных ОА расщепление коллагена 2 типа подавлялось ПГЕ2 в концентрации 10 пг/мл, а также 5нг/мл трансформирующего ростового фактора (ТРФ) β2. Подавления деградации протеогликана (аггрекана) при данной концентрации ПГЕ2 не происходило. Анализ экспрессии генов у 5 ОА пациентов показал, что 10пг/мл ПГЕ2 подавлял экспрессию металломонооксигеназы (ММП)-13 и ММП-1, а также провоспалительных цитокинов: интерлейкина (ИЛ)-1β и фактора некроза опухоли (ФНО)α, и маркера гипертрофии хондроцитов - коллагена 10 типа (COL10A1). Напроксен, неселективный ингибитор циклооксиге-18 назы (COX)-1 и –2, в концентрации от 5 до 30мкг/мл блокировал индуцированное TРФβ2 ингибирование расщепления коллагена, указывая, что ПГЕ2 опосредует влияние этого ростового фактора. Сам напроксен в концентрации 5мкг/мл увеличивал разрушение коллагена. Заключение. Проведенное исследование показало, что ПГЕ2 в концентрации гораздо ниже наблюдаемых при воспалении является хондропротектором, поскольку способен селективно подавлять разрушение коллагена в хряще больных OA. Кроме того, гипертрофия хондроцитов хряща при ОА, функционально связанная с усиленным расщеплением коллагена, также регулируется низкими концентрациями ПГЕ2.

остеоартроз, суставной хрящ, деградация коллагена 2 типа, простагландин Е2, экспрессия генов, напроксен

1. <div><p>Poole A.R. Cartilage in health and disease. In Arthritis and Allied Conditions: A Textbook of Rheumatology, 15th Edition, Edited by Koopman WJ, Moreland LW. Baltimore:Williams &amp; Wilkins; 2005, 223-69.</p><p>Tchetina E.V., Squires G., Poole A.R. Increased type II collagen degradation and very early focal cartilage degeneration is associated with the upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J. Rheumatol., 2005, 32, 876-86.</p><p>Tchetina E.V., Antoniou J., Tanzer M., et al. Transforming growth factor – β2 suppresses collagen cleavage in cultured human osteoarthritic cartilage, reduces expression of genes associated with chon- drocyte hypertrophy and degradation, and increases prostaglandin E2 production. Am. J. Pathol., 2006, 168, 131-40.</p><p>Luo C., He M-L., Bohlin L. Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain contro- versial. Acta Pharmacol. Sinica, 2005, 26, 926-33.</p><p>Knott I., Dieu M., Burton M., et al. Induction of cyclooxygenase by interleukin 1: Comparative study between human synovial cells and chondrocytes. J. Rheumatol., 1994, 21, 426-36.</p><p>Amin A.R., Attur M., Patel R.N., et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis- affected cartilage. Influence of nitric oxide. J. Clin. Invest., 1997, 99, 1231-7.</p><p>Martel-Pelletier J., Pelletier J-P., Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tis- sues. Seminars Arthritis Rheum., 2003, 33, 155-67.</p><p>Gilroy D.W., Colville-Nash P.R., Willis D., et al. Inducible cyclooxygenase may have anti-inflammato- ry properties. Nat. Med., 1999, 5, 698-701.</p><p>DiBattista J.A., Martel-Pelletier J., Fujimoto N., et al. Prostaglandins E2 and E1 inhibit cytokine-induced metalloproteinase expression in human synovial fibro- blasts. Mediation by cyclic-AMP signaling pathway. Lab. Invest., 1994, 71, 270-8.</p><p>Salvatory R., Guidon P.T., Rapuano B.E., et al. Prostaglandin E1 inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts. Endocrinol., 1992, 131, 21-8.</p><p>Lowe G.N., Fu Y.H., McDougall S., et al. Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: Role of second messengers. Endocrinol., 1996, 137, 2208-16.</p><p>DiBattista J.A., Dore S., Martel-Pelletier J., et al. Prostaglandin E2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: identification of an effector autocrine loop involving insulin-like growth factor 1. Mol. Cell. Endocrinol., 1996, 123, 27-35.</p><p>Mastbergen S.C., Jansen N.W.D., Bijisma J.W.J., et al. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoar- thritic cartilage:an in vitro study. Arthritis Res. Ther., 2006, 8, R2 (doi:10.1186/ar1846).</p><p>DiBattista J.A., Martel-Pelletier J., Cloutier J.M., et al. Modulation of glucocorticoid receptor expression in human articular chondrocytes by cAMP and prosta- glandins. J. Rheumatol., 1991, 27, 102-5.</p><p>Altman R., Asch E., Bloch D., et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum., 1986, 29, 1039-149.</p><p>Billinghurst R.C., Dahlberg L., Wu W., et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum., 2000, 43, 664-72.</p><p>Billinghurst R.C., Dahlberg L., Ionescu M., et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest., 1997, 99, 1534-45.</p><p>Dahlberg L., Billinghurst R.C., Manner P., et al. Selective enhancement of collagenase-mediated clea- vage of resident type II collagen in cultured osteoar- thritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). 23 Arthritis Rheum., 2000, 43, 673-82.</p><p>Farndale R.W., Buttle G.J., Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta, 1986, 883, 173-77.</p><p>Rizkalla G., Reiner A., Bogoch E., et al. Studies of the articular cartilage proteoglycan aggrecan in health and arthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J. Clin. Invest., 1992, 90, 2268-77.</p><p>Pairet M., Churchill L., Engelhardt G. Differential inhibition of cyclooxygenase 1 and 2 by NSAIDS. In New Targets of Inflammation: Inhibitors of COX-2 and Adhesion Molecules, Edited by Bazan N, Botting J, Vane J. Hingham, MA, Kluwer Academic Publishers; 1996, 23-46.</p><p>DiBattista J.A., Pelletier J-P., Ranger P., et al. Modulation of the expression of glucocorticoid recep- tors in synovial fibroblasts and chondrocytes by pros- taglandins and NSAIDS. Am. J. Therap., 1995, 2, 369-73.</p><p>Aoyama T., Liang B., Okamoto T., et al. PGE2 signal through EP2 promotes the growth of articular chondro- cytes. J. Bone Miner. Res., 2005, 20, 377-89.</p><p>Li T-F., Zuscik M.J., Ionescu A.M., et al. PGE2 inhibits chondrocyte differentiaiton through PKA and PKC signaling. Exp. Cell Res., 2004, 300, 159-69.</p><p>Zhang X., Ziran N., Goater J.J., et al. Primary murine limb bud mesenchimal cells in long-term culture com- plete chondrocyte differentiation: TGF-β delays hypertrophy and PGE2 inhibits terminal differentiation. Bone, 2004, 34, 809-17.</p><p>O’Keefe R.J., Crabb I.D., Puzas J.E., et al. Influence of prostaglandins on DNA and matrix synthesis in growth plate chondrocytes. J. Bone Miner. Res., 1992, 7, 397-404.</p><p>Bunning R.A., Russell R.G. The effect of tumor necrosis factor alpha and gamma-interferon production of prostaglandin E and of caseinase activity by human articular chondrocytes. Arthritis Rheum., 1989, 32, 780-4.</p><p>Blanco F.J., Lotz M. IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp. Cell Res., 1995, 218, 319-25.</p><p>Lorenz J.J., Furdon P.J., Taylor J.D., et al. A cyclic adenosine 3’,5’-monophosphate signal is required for the induction of IL-1 beta by TNF-alpha in human monocytes. J. Immunol., 1995, 155, 836-44.</p><p>Miwa M., Saura R., Hirata S., et al. Induction of apoptosis in bovine articular chondrocyte by pros- taglandin E2 through cAMP-dependent pathway. Osteoarthr. Cartil., 2000, 8, 17-24.</p><p>Tung J.T., Arnold C.E., Alexander L.H., et al. Evaluation of the influence of prostaglandin E2 on recombinant equine interleukin-1beta-stimulated matrix metalloproteinases 1, 3 and 13 and tissue inhibitior of matrix metalloproteinase 1 expression in equine chondrocyte cultures. Am. J. Vet. Res., 2002, 63, 987-93.</p><p>Faour W.H., He Q., Mancini A., et al. Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts: role in suppression of c/EBP/NF-{kappa} B-mediated MEKK1-induced MMP-1 expression. J. Biol. Chem., 2006, 281, 19849-60.</p><p>Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metast. Rev., 2000, 19, 19-27.</p><p>Schwartz Z., Gilley R.M., Sylvia V.L., et al. The effect of prostaglandin E2 on costochondral chon- drocyte differentiation is mediated by cyclic ade- nosine 3’,5’-monophosphate and protein kinase C. Endocrinol., 1998, 139, 1825-34.</p><p>Watkins B.A., Li Y., Seifert M.F. Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology. J. Am. College Nutr., 2001, 20, 410S-6S.</p><p>Yasuda T., Tchetina E., Ohsawa K., et al. Peptides of type II collagen can induce the cleavage of type II col- lagen and aggrecan in articular cartilage. Matrix Biol., 2006, 25, 419-29.</p></div><br />